Is Avatrombopag/Suxin a peptide drug?

Avatrombopag is an oral thrombopoietin receptor agonist, which is a small molecule non-peptide drug rather than a peptide drug. Its main function is to promote the differentiation and proliferation of bone marrow megakaryocytes by simulating the activation of receptors by thrombopoietin (TPO), thereby increasing platelet production. Different from peptide drugs, the molecular structure of avatrombopag is a small molecule chemical synthesis product with high stability and can be administered orally, avoiding the usual limitations of gastrointestinal degradation, injection dependence and short half-life of peptide drugs.

PolypeptidesTPO receptor agonists, such asEltrombopag (Eltrombopag) and recombinant TPO (rhTPO), usually require injection or oral administration of specific preparations to work. Avatrombopag achieves its agonistic function by combining small molecules with receptors. It has a high oral absorption rate and its metabolic pathway is mainly through the liver CYP enzyme system. It has good bioavailability and blood concentration stability. This feature gives it obvious advantages in applications such as chronic liver disease, thrombocytopenia, and aplastic anemia.

Overseas clinical practice shows that avatrombopag is well tolerated, and common adverse reactions are mainly mild to moderate headache, fatigue and slight fluctuations in liver function indicators. The drug does not have a protein or polypeptide structure and will not cause the production of anti-drug antibodies, so it is safe for long-term use. For patients with AA or chronic liver disease-related thrombocytopenia, avatrombopag is an oral small molecule drug that is easy to use and its efficacy can be evaluated through routine blood monitoring.

In summary, avatrombopag is a small molecule thrombopoietin receptor agonist rather than a peptide drug. Its oral advantages, stability and high bioavailability make it of significant application value in the treatment of immune thrombocytopenia (ITP), providing patients with a safer, more convenient and controllable treatment option. This characteristic has also prompted its attention in aplastic anemia and other hematological diseases, providing new ideas for precision treatment.

Reference materials:https://go.drugbank.com/drugs/DB11995